Zymeworks (ZYME) News Today $11.43 +0.43 (+3.91%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vanguard Group Inc. Lowers Stock Holdings in Zymeworks Inc. (NYSE:ZYME)Vanguard Group Inc. lowered its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,493,288 shares of the company's stApril 15 at 3:15 AM | marketbeat.comWellington Management Group LLP Has $3.21 Million Stake in Zymeworks Inc. (NYSE:ZYME)Wellington Management Group LLP lessened its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,098 shares of the company's stApril 14 at 3:41 AM | marketbeat.comAmerican Century Companies Inc. Takes Position in Zymeworks Inc. (NYSE:ZYME)American Century Companies Inc. acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 39,942 shares of the company's stock, valued at approximately $585,000. American CentuApril 14 at 3:11 AM | marketbeat.com201,700 Shares in Zymeworks Inc. (NYSE:ZYME) Bought by Norges BankNorges Bank purchased a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 201,700 shares of the company's stock, valued at approximately $2,953,000April 13 at 4:03 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA lessened its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 65.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,385 shares of the company's stock after selling 52,471 sharApril 12 at 4:44 AM | marketbeat.comTrexquant Investment LP Invests $1.49 Million in Zymeworks Inc. (NYSE:ZYME)Trexquant Investment LP purchased a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 101,996 shares of the company's stock, valued at approximately $1,493,April 12 at 4:41 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Acquires $2,194,212.46 in StockApril 10, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from AnalystsApril 10, 2025 | americanbankingnews.comZymeworks (NYSE:ZYME) Stock Price Down 7.6% - What's Next?Zymeworks (NYSE:ZYME) Stock Price Down 7.6% - Here's What HappenedApril 9, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 196,438 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 196,438 shares of Zymeworks stock in a transaction dated Friday, April 4th. The shares were purchased at an average price of $11.17 per share, for a total transaction of $2,194,212.46. Following the completion of the transaction, the director now directly owns 17,699,774 shares in the company, valued at approximately $197,706,475.58. The trade was a 1.12 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.April 9, 2025 | marketbeat.comZymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff RolloutApril 9, 2025 | insidermonkey.comEcor1 Capital, Llc Buys 196,438 Shares of Zymeworks Inc. (NYSE:ZYME) StockApril 8, 2025 | insidertrades.comZymeworks Inc. (NYSE:ZYME) Receives Average Recommendation of "Moderate Buy" from AnalystsZymeworks Inc. (NYSE:ZYME - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, five have given a buy recommendationApril 8, 2025 | marketbeat.comSchroder Investment Management Group Makes New $4.89 Million Investment in Zymeworks Inc. (NYSE:ZYME)Schroder Investment Management Group acquired a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 337,161 shares of the company's stock, valuApril 7, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 60,642 Zymeworks Inc. (NYSE:ZYME)Raymond James Financial Inc. acquired a new position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,642 shares of the company's stock, valued atApril 6, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 4,397 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 4,397 shares of Zymeworks stock in a transaction dated Monday, March 31st. The shares were bought at an average price of $11.75 per share, for a total transaction of $51,664.75. Following the acquisition, the director now owns 17,259,548 shares in the company, valued at approximately $202,799,689. This trade represents a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.April 4, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 74,360 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 74,360 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was purchased at an average price of $11.85 per share, with a total value of $881,166.00. Following the completion of the purchase, the director now owns 17,382,566 shares in the company, valued at approximately $205,983,407.10. This trade represents a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.April 4, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $51,664.75 in StockApril 3, 2025 | insidertrades.comZymeworks Inc. sees insider purchases totaling $1.5 millionApril 2, 2025 | investing.comEcor1 Capital, Llc Buys 43,848 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 43,848 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of $12.24 per share, for a total transaction of $536,699.52. Following the transaction, the director now owns 17,255,151 shares of the company's stock, valued at $211,203,048.24. The trade was a 0.25 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.March 28, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 43,848 Shares of StockMarch 28, 2025 | insidertrades.comZymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingMarch 26, 2025 | finanznachrichten.deInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26, 2025 | 247wallst.comZymeworks to Engage Investors at Upcoming ConferencesMarch 26, 2025 | tipranks.comZymeworks Announces Participation in Upcoming Investor ConferencesMarch 26, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Acquires $296,772.12 in StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average price of $13.08 per share, for a total transaction of $296,772.12. Following the transaction, the director now directly owns 17,157,802 shares in the company, valued at $224,424,050.16. This represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 25, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $396,601.74 in StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 31,033 shares of the stock in a transaction dated Friday, March 21st. The stock was acquired at an average price of $12.78 per share, with a total value of $396,601.74. Following the completion of the acquisition, the director now owns 17,135,113 shares in the company, valued at approximately $218,986,744.14. The trade was a 0.18 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.March 25, 2025 | marketbeat.comZymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in MarchMarch 25, 2025 | msn.comZymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingMarch 25, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 22,689 SharesMarch 25, 2025 | insidertrades.comHillsdale Investment Management Inc. Purchases Shares of 230,025 Zymeworks Inc. (NYSE:ZYME)Hillsdale Investment Management Inc. acquired a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 230,025 shares of the company's stock, valued at approximately $3,368,000. HillsdMarch 24, 2025 | marketbeat.comBank of New York Mellon Corp Has $1.77 Million Stock Holdings in Zymeworks Inc. (NYSE:ZYME)Bank of New York Mellon Corp cut its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 51.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,683 shares of the company's stock after selling 129,30March 23, 2025 | marketbeat.comInsiders Are Spending Big: 15 Stocks Leading in MarchMarch 22, 2025 | insidermonkey.comQ1 Earnings Forecast for Zymeworks Issued By Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will post earningMarch 21, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 56,277 Shares of StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 56,277 shares of the stock in a transaction on Monday, March 17th. The stock was bought at an average price of $12.23 per share, for a total transaction of $688,267.71. Following the completion of the purchase, the director now directly owns 16,858,418 shares in the company, valued at approximately $206,178,452.14. The trade was a 0.33 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 58,306 SharesZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 58,306 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average price of $12.64 per share, with a total value of $736,987.84. Following the purchase, the director now owns 17,030,604 shares of the company's stock, valued at approximately $215,266,834.56. The trade was a 0.34 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.March 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 56,277 SharesMarch 20, 2025 | insidertrades.comPlatinum Investment Management Ltd. Has $4.49 Million Holdings in Zymeworks Inc. (NYSE:ZYME)Platinum Investment Management Ltd. trimmed its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 6.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 306,460 shares of the company's stock after selling 21,062 sharesMarch 20, 2025 | marketbeat.comTejara Capital Ltd Invests $564,000 in Zymeworks Inc. (NYSE:ZYME)Tejara Capital Ltd purchased a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 38,537 shares of the company's stock, valued at approximately $564,000. Tejara CapMarch 19, 2025 | marketbeat.comPicton Mahoney Asset Management Reduces Holdings in Zymeworks Inc. (NYSE:ZYME)Picton Mahoney Asset Management lowered its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 15.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 206,569 shares of the company's stock after selling 38March 17, 2025 | marketbeat.comLifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)March 15, 2025 | markets.businessinsider.comHuge Insider Buying: Victoria's Secret, Carl Icahn, and MoreMarch 15, 2025 | 247wallst.comMonaco Asset Management SAM Reduces Position in Zymeworks Inc. (NYSE:ZYME)Monaco Asset Management SAM cut its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 95.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company's stock after selling 285,000March 15, 2025 | marketbeat.comEcor1 Capital, Llc Buys 320,690 Shares of Zymeworks Inc. (NYSE:ZYME) StockZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 320,690 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were acquired at an average price of $11.49 per share, for a total transaction of $3,684,728.10. Following the completion of the transaction, the director now owns 16,040,851 shares in the company, valued at approximately $184,309,377.99. This trade represents a 2.04 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 14, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 468,356 SharesZymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 468,356 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was purchased at an average price of $12.48 per share, with a total value of $5,845,082.88. Following the purchase, the director now directly owns 16,802,141 shares of the company's stock, valued at $209,690,719.68. The trade was a 2.87 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.March 14, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 320,690 Shares of StockMarch 14, 2025 | insidertrades.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalZymeworks Inc. (NYSE:ZYME - Free Report) - Equities research analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for shares of Zymeworks in a research report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings perMarch 14, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Jupiter Asset Management Ltd.Jupiter Asset Management Ltd. cut its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 13.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 369,499 shares of the company's stock after selling 57,445March 14, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesZymeworks Inc. (NYSE:ZYME - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a stronMarch 13, 2025 | marketbeat.comZymeworks (ZYME) Shares Surge Amid Positive Analyst ForecastsMarch 12, 2025 | markets.businessinsider.com Remove Ads Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Media Mentions By Week ZYME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼1.210.80▲Average Medical News Sentiment ZYME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼115▲ZYME Articles Average Week Remove Ads Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News MRUS News OGN News MOR News SWTX News CRNX News CPRX News PTGX News VKTX News SRRK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZYME Stock Free ZYME Stock Alerts